944718-22-3

Basic information

• Product Name: 1-(5-broMopyridin-2-yl)cyclopropanaMine
• Synonyms: 1-(5-broMopyridin-2-yl)cyclopropanaMine
• CAS NO: 944718-22-3
• Molecular Formula: C8H9BrN2
• Molecular Weight: 213.07446
• Mol File: 944718-22-3.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(5-broMopyridin-2-yl)cyclopropanaMine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5-broMopyridin-2-yl)cyclopropanaMine(944718-22-3)
• EPA Substance Registry System: 1-(5-broMopyridin-2-yl)cyclopropanaMine(944718-22-3)

Safety Data

• Hazardous Substances Data: 944718-22-3(Hazardous Substances Data)

Usage

Description

1-(5-bromopyridin-2-yl)cyclopropanamine is a chemical compound with the molecular formula C8H10BrN. It is a cyclopropanamine derivative containing a bromopyridine group. 1-(5-broMopyridin-2-yl)cyclopropanaMine is characterized by its unique cyclopropanamine moiety and bromopyridine group, which can confer distinct properties to the molecules it is incorporated into.

Uses

Used in Medicinal Chemistry:
1-(5-bromopyridin-2-yl)cyclopropanamine is used as a building block for the synthesis of various biologically active molecules. Its cyclopropanamine moiety can provide unique properties to the molecules it is incorporated into, making it a valuable tool for the development of novel pharmaceuticals and chemical probes.
Used in Drug Discovery:
1-(5-bromopyridin-2-yl)cyclopropanamine is used as a key intermediate in the synthesis of new drug candidates. Its bromopyridine group offers potential for further functionalization and diversification of the compound, enhancing its utility in synthetic chemistry and the discovery of new therapeutic agents.
Used in Chemical Probes Development:
1-(5-bromopyridin-2-yl)cyclopropanamine is used as a component in the development of chemical probes. The incorporation of this compound into molecules can lead to the discovery of new biological targets and pathways, contributing to a better understanding of disease mechanisms and the identification of potential therapeutic interventions.

Upstream product

• 90145-48-5 5-bromo-2-pyridinecarboxamide 
• 30766-11-1 5-bromoisonicotinic acid 
• 925-90-6 ethylmagnesium bromide 
• 97483-77-7 2-Cyano-5-bromopyridine 

Relevant articles and documents

SULFONAMIDE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG

The present invention relates to Sulfonamide Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, W, X, R1, R2, R3, R4 and R5 are as defined herein. The present invention also relates to compositions comprising at least one Sulfonamide Derivative, and methods of using the Sulfonamide Derivatives for improving the pharmacokinetics of a drug.

SULFONAMIDE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG

The present invention relates to Sulfonamide Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, W, X, R1, R2, R3, R4 and R5 are as defined herein. The present invention also relates to compositions comprising at least one Sulfonamide Derivative, and methods of using the Sulfonamide Derivatives for improving the pharmacokinetics of a drug.

PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS

The invention relates pyridine amide derivative of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently hydrogen, linear o branched (C1-C3)alkyl or joined together they form a cyclopropyl ring; R is independently selected from the group consisting of halogens and trifluoromethyl and p is 1, 2 or 3; A is C or N; E is a group of formula (B) or (C), wherein B is C(O)OH, C(O)O(C1-C3)alkyl, and C is selected from the group consisting of formula (I) m is 1,2 or 3, n is 0 or 1, W is —O—, —O(C1-C3 alkyl)-; —(C1-C3 alkyl)O—; —C(O)—; —C(═N—O(C1-C3 alkyl))-; —NH— or —NH(C1-C3alkyl)-; Ar is phenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, methyl, —NH(C1-C3alkyl)-; —N(C1-C3alkyl)(C1-C3alkyl)-, a from 5 to 7 membered heterocyclic ring containing one nitrogen atom which is covalently bonded to Ar and optionally containing one or two heteroatoms selected from N, O and S; and a 5- or 6-membered heteroaromatic ring containing 1 to 3 heteroatoms selected from S, O e N, such heteroaromatic ring being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl. The compounds of the invention could be used for manufacturing a medicament for the treatment of pathologies which require the use of an antagonist of the EP4 receptor, such as the treatment of acute and chronic pain, inflammatory pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer, endometriosis and migraine.